Aasma Shaukat, MD, MPH, Robert M. and Mary H. Glickman professor of Medicine and Gastroenterology, Department of Medicine, professor, Department of Population Health, co-director, Translational Research Education and Careers, director, Outcomes Research, Division of Gastroenterology and Hepatology, NYU Grossman School of Medicine, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer (CRC).

The PREEMPT CRC trial (NCT04369053) is a prospective, multi-center, observational trial evaluating a blood-based test for its ability to detect CRC. Samples are collected from average-risk patients receiving a routine screening colonoscopy.

From the outset of the study, the trial design encouraged the inclusion of a diverse representation of the population in terms of geography, age groups, gender, race, and ethnicity, Shaukat says, adding that investigators focused on finding treatment sites that would allow for diverse enrollment across those groups.

Investigators deliberately selected locations that had higher rates of diversity so that results from the trial would be more representative of the real-world population, Shaukat concludes.

Videos

Aasma Shaukat, MD, MPH, discusses the benefit of diverse enrollment in clinical trials in colorectal cancer.


Dr. Shaukat on the Benefit of Diverse Enrollment in Clinical Trials in CRC

Aasma Shaukat, MD, MPH, Robert M. and Mary H. Glickman professor of Medicine and Gastroenterology, Department of Medicine, professor, Department of Population Health, co-director, Translational Research Education and Careers, director, Outcomes Research, Division of Gastroenterology and Hepatology, NYU Grossman School of Medicine, discusses the methods utilized in the PREEMPT CRC trial (NCT04369053) in colorectal cancer (CRC).

PREEMPT CRC is a prospective, multi-center, observational trial evaluating a blood-based test for its ability to detect CRC. Samples are collected from average-risk patients receiving a routine screening colonoscopy.

The study is designed to validate the blood-based test by comparing results against those from a standard colonoscopy, which is still considered the gold standard for screening for CRC, Shaukat says. In addition to being average risk, all patients are at least 45 years old who are scheduled to undergo a screening colonoscopy, Shaukat explains.

The blood test is administered prior to the colonoscopy, and patients provide basic background information as a part of the study, Shaukat continues. The main goal of the study is to evaluate the accuracy of the blood-based test, specifically in its ability to detect advanced adenomas and early CRC, Shaukat concludes.

Aasma Shaukat, MD, MPH, discusses the methods utilized in the PREEMPT CRC trial in colorectal cancer.


Aasma Shaukat, MD

Articles

Dr. Shaukat on the Benefit of Diverse Enrollment in Clinical Trials in CRC

Dr. Shaukat on the Methods Utilized in the PREEMPT-CRC Trial in CRC